Gemin X raises $16 million to fund development of mid-stage Bcl-2 inhibitor
This article was originally published in Scrip
Executive Summary
Gemin X Pharmaceuticals has raised $16 million in a series D financing. The proceeds will be used to fund clinical development of its lead product candidate, obatoclax, in patients with small-cell lung cancer (SCLC).